Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer : Episode 7
Opinion
Video
Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies
Author(s):
Experts on breast cancer discuss the potential adverse events related to trastuzumab deruxtecan (T-DXd).
EP: 1.Overview of Current ADCs in Breast Cancer
EP: 2.ADCs in Breast Cancer: Mechanism of Action, and Components
EP: 3.Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials
EP: 4.Expert Perspectives on the Management of SG-Related Neutropenia
EP: 5.Navigating SG-related Diarrhea
EP: 6.Expert Insights: SG Adverse Events Management including Alopecia & Nausea
Now Viewing
EP: 7.Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies
EP: 8.Clinical Management Considerations: Pneumonitis associated with T-DXd
Video content above is prompted by the following:
- Can you describe the cardiotoxicity risk with T-DXd and the mechanism behind cardiovascular toxicity?
- Please comment on your monitoring strategy for cardiotoxicity with T-DXd.
- What patient symptoms do you monitor for? What are your left ventricular ejection fraction cutoffs to initiate, hold/delay, and discontinue therapy?
Related Videos
Related Content
